Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma

Correlation with clinicopathological parameters

M. F. Cheng, C. Tzao, W. C. Tsai, W. H. Lee, A. Chen, H. Chiang, L. F. Sheu, J. S. Jin

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Extracellular matrix metalloproteinase inducer (EMMPRIN) and the type II transmembrane serine protease, matriptase, are expressed in several human cancers and play an important role in tumor progression. The aim of the present study was to investigate the immuno-staining patterns of EMMPRIN and matriptase in patients with esophageal squamous cell carcinomas (SCC) and correlate the percentage tumor staining with tumor differentiation and clinical parameters. EMMPRIN and matriptase immunoreactivity was seen on the cell membrane and in the cytoplasm of tumor cells in all 41 cases of esophageal SCC evaluated. The percentage tumor staining of EMMPRIN was 48±3% for well differentiated, 73±3% for moderately differentiated, and 92±3% for poorly differentiated esophageal SCC. Higher percentage tumor staining with EMMPRIN correlated significantly with poorly differentiated esophageal SCC (P <0.05). The percentage tumor staining with matriptase correlated significantly with tumor differentiation (52±3% for well differentiated, 85±2% for moderately differentiated, and 88±3% for poorly differentiated esophageal SCC). Additionally, higher percentage tumor staining with matriptase was significantly correlated with the advanced N and M stages (P <0.05). Our results demonstrate that EMMPRIN and matriptase are over-expressed in esophageal SCC and are correlated with advanced clinicopathological stages. Pharmacological agents targeting EMMPRIN and matriptase expressions may be beneficial in the treatment of esophageal SCC.

Original languageEnglish
Pages (from-to)482-486
Number of pages5
JournalDiseases of the Esophagus
Volume19
Issue number6
DOIs
Publication statusPublished - Dec 2006
Externally publishedYes

Fingerprint

CD147 Antigens
Neoplasms
Staining and Labeling
Esophageal Squamous Cell Carcinoma
matriptase
Serine Proteases
Cytoplasm

Keywords

  • CD147
  • EMMPRIN
  • Esophagus
  • Matriptase
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma : Correlation with clinicopathological parameters. / Cheng, M. F.; Tzao, C.; Tsai, W. C.; Lee, W. H.; Chen, A.; Chiang, H.; Sheu, L. F.; Jin, J. S.

In: Diseases of the Esophagus, Vol. 19, No. 6, 12.2006, p. 482-486.

Research output: Contribution to journalArticle

Cheng, M. F. ; Tzao, C. ; Tsai, W. C. ; Lee, W. H. ; Chen, A. ; Chiang, H. ; Sheu, L. F. ; Jin, J. S. / Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma : Correlation with clinicopathological parameters. In: Diseases of the Esophagus. 2006 ; Vol. 19, No. 6. pp. 482-486.
@article{873d614618294a5d8d232b8dce9e068b,
title = "Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: Correlation with clinicopathological parameters",
abstract = "Extracellular matrix metalloproteinase inducer (EMMPRIN) and the type II transmembrane serine protease, matriptase, are expressed in several human cancers and play an important role in tumor progression. The aim of the present study was to investigate the immuno-staining patterns of EMMPRIN and matriptase in patients with esophageal squamous cell carcinomas (SCC) and correlate the percentage tumor staining with tumor differentiation and clinical parameters. EMMPRIN and matriptase immunoreactivity was seen on the cell membrane and in the cytoplasm of tumor cells in all 41 cases of esophageal SCC evaluated. The percentage tumor staining of EMMPRIN was 48±3{\%} for well differentiated, 73±3{\%} for moderately differentiated, and 92±3{\%} for poorly differentiated esophageal SCC. Higher percentage tumor staining with EMMPRIN correlated significantly with poorly differentiated esophageal SCC (P <0.05). The percentage tumor staining with matriptase correlated significantly with tumor differentiation (52±3{\%} for well differentiated, 85±2{\%} for moderately differentiated, and 88±3{\%} for poorly differentiated esophageal SCC). Additionally, higher percentage tumor staining with matriptase was significantly correlated with the advanced N and M stages (P <0.05). Our results demonstrate that EMMPRIN and matriptase are over-expressed in esophageal SCC and are correlated with advanced clinicopathological stages. Pharmacological agents targeting EMMPRIN and matriptase expressions may be beneficial in the treatment of esophageal SCC.",
keywords = "CD147, EMMPRIN, Esophagus, Matriptase, Squamous cell carcinoma",
author = "Cheng, {M. F.} and C. Tzao and Tsai, {W. C.} and Lee, {W. H.} and A. Chen and H. Chiang and Sheu, {L. F.} and Jin, {J. S.}",
year = "2006",
month = "12",
doi = "10.1111/j.1442-2050.2006.00613.x",
language = "English",
volume = "19",
pages = "482--486",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma

T2 - Correlation with clinicopathological parameters

AU - Cheng, M. F.

AU - Tzao, C.

AU - Tsai, W. C.

AU - Lee, W. H.

AU - Chen, A.

AU - Chiang, H.

AU - Sheu, L. F.

AU - Jin, J. S.

PY - 2006/12

Y1 - 2006/12

N2 - Extracellular matrix metalloproteinase inducer (EMMPRIN) and the type II transmembrane serine protease, matriptase, are expressed in several human cancers and play an important role in tumor progression. The aim of the present study was to investigate the immuno-staining patterns of EMMPRIN and matriptase in patients with esophageal squamous cell carcinomas (SCC) and correlate the percentage tumor staining with tumor differentiation and clinical parameters. EMMPRIN and matriptase immunoreactivity was seen on the cell membrane and in the cytoplasm of tumor cells in all 41 cases of esophageal SCC evaluated. The percentage tumor staining of EMMPRIN was 48±3% for well differentiated, 73±3% for moderately differentiated, and 92±3% for poorly differentiated esophageal SCC. Higher percentage tumor staining with EMMPRIN correlated significantly with poorly differentiated esophageal SCC (P <0.05). The percentage tumor staining with matriptase correlated significantly with tumor differentiation (52±3% for well differentiated, 85±2% for moderately differentiated, and 88±3% for poorly differentiated esophageal SCC). Additionally, higher percentage tumor staining with matriptase was significantly correlated with the advanced N and M stages (P <0.05). Our results demonstrate that EMMPRIN and matriptase are over-expressed in esophageal SCC and are correlated with advanced clinicopathological stages. Pharmacological agents targeting EMMPRIN and matriptase expressions may be beneficial in the treatment of esophageal SCC.

AB - Extracellular matrix metalloproteinase inducer (EMMPRIN) and the type II transmembrane serine protease, matriptase, are expressed in several human cancers and play an important role in tumor progression. The aim of the present study was to investigate the immuno-staining patterns of EMMPRIN and matriptase in patients with esophageal squamous cell carcinomas (SCC) and correlate the percentage tumor staining with tumor differentiation and clinical parameters. EMMPRIN and matriptase immunoreactivity was seen on the cell membrane and in the cytoplasm of tumor cells in all 41 cases of esophageal SCC evaluated. The percentage tumor staining of EMMPRIN was 48±3% for well differentiated, 73±3% for moderately differentiated, and 92±3% for poorly differentiated esophageal SCC. Higher percentage tumor staining with EMMPRIN correlated significantly with poorly differentiated esophageal SCC (P <0.05). The percentage tumor staining with matriptase correlated significantly with tumor differentiation (52±3% for well differentiated, 85±2% for moderately differentiated, and 88±3% for poorly differentiated esophageal SCC). Additionally, higher percentage tumor staining with matriptase was significantly correlated with the advanced N and M stages (P <0.05). Our results demonstrate that EMMPRIN and matriptase are over-expressed in esophageal SCC and are correlated with advanced clinicopathological stages. Pharmacological agents targeting EMMPRIN and matriptase expressions may be beneficial in the treatment of esophageal SCC.

KW - CD147

KW - EMMPRIN

KW - Esophagus

KW - Matriptase

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=33750485799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750485799&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2050.2006.00613.x

DO - 10.1111/j.1442-2050.2006.00613.x

M3 - Article

VL - 19

SP - 482

EP - 486

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 6

ER -